3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1
2
Phase 2/3
1
Status
Recruiting
2
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Tumor-Agnostic
1
Sarcoma
1
Genitourinary
1
Conditions
Melanoma
10
Urinary Bladder Neoplasms
3
Stomach Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Carcinoma, Basal Cell
2
Advanced Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Spinocerebellar Degenerations
1
Sarcoma
1
Interventions
Gemcitabine
53
Bevacizumab
52
Cyclophosphamide
49
Docetaxel
42
Carboplatin
40
pembrolizumab
37
Paclitaxel
36
Fluorouracil
36
Cisplatin
35
Radiotherapy
31
Oxaliplatin
31
Capecitabine
29
Irinotecan
28
Dexamethasone
27
Leucovorin
25
Cetuximab
25
Nivolumab
24
Doxorubicin
22
Drug Therapy
21
Erlotinib Hydrochloride
20
Pemetrexed
19
durvalumab
18
trametinib
17
fludarabine
16
atezolizumab
16
Trastuzumab
16
Sunitinib
16
Rituximab
16
Prednisone
16
Sorafenib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms
×
relatlimab
×
Clear all
NCT03899155
2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2
Recruiting
1,500 enrolled
NCT04095208
2026-04-21
CONGRATS
Institut Bergonié
Phase 2
Completed
68 enrolled
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled